These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 29737896)

  • 21. Anti IL-17 in psoriasis.
    Ly K; Smith MP; Thibodeaux Q; Reddy V; Liao W; Bhutani T
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1185-1194. PubMed ID: 31603358
    [No Abstract]   [Full Text] [Related]  

  • 22. Review of IL-17 inhibitors for psoriasis.
    Amin M; Darji K; No DJ; Bhutani T; Wu JJ
    J Dermatolog Treat; 2018 Jun; 29(4):347-352. PubMed ID: 29058501
    [No Abstract]   [Full Text] [Related]  

  • 23. Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
    Canavan TN; Elmets CA; Cantrell WL; Evans JM; Elewski BE
    Am J Clin Dermatol; 2016 Feb; 17(1):33-47. PubMed ID: 26649440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-17 for therapy.
    Kurschus FC; Moos S
    J Dermatol Sci; 2017 Sep; 87(3):221-227. PubMed ID: 28633806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-IL-17 Agents for Psoriasis: A Review of Phase III Data.
    Farahnik B; Beroukhim K; Nakamura M; Abrouk M; Zhu TH; Singh R; Lee K; Bhutani T; Koo J
    J Drugs Dermatol; 2016 Mar; 15(3):311-6. PubMed ID: 26954316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways.
    Molinelli E; Campanati A; Brisigotti V; Offidani A
    Curr Pharm Biotechnol; 2017; 18(12):964-978. PubMed ID: 29299984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis.
    Azevedo A; Torres T
    Actas Dermosifiliogr; 2017 May; 108(4):305-314. PubMed ID: 27887675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
    Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
    J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis.
    Blauvelt A
    Expert Opin Biol Ther; 2016; 16(2):255-63. PubMed ID: 26666707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New and emerging therapies in psoriasis.
    Leonardi CL; Gordon KB
    Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S37-41. PubMed ID: 24979544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
    Blauvelt A; Papp KA; Griffiths CEM; Puig L; Weisman J; Dutronc Y; Kerr LF; Ilo D; Mallbris L; Augustin M
    Am J Clin Dermatol; 2017 Apr; 18(2):273-280. PubMed ID: 28074446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions.
    Wu KK; Lee MP; Lee EB; Wu JJ
    J Dermatolog Treat; 2020 Jun; 31(4):359-365. PubMed ID: 30900514
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunogenicity and skin clearance recapture in clinical studies of brodalumab.
    Bagel J; Lebwohl M; Israel RJ; Jacobson A
    J Am Acad Dermatol; 2020 Feb; 82(2):344-351. PubMed ID: 31175910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential interleukin-17 inhibitors for moderate-to-severe plaque psoriasis who have an IL-17 inhibitors failure in a resource limited country: An economic evaluation.
    Dilokthornsakul P; Sawangjit R; Noppakun N; Rajatanavin N; Pattamadilok B; Chularojanamontri L; Permsuwan U
    PLoS One; 2024; 19(8):e0307050. PubMed ID: 39121033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
    Puig L
    Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.
    Sherman S; Solomon Cohen E; Amitay-Laish I; Hodak E; Pavlovsky L
    Acta Derm Venereol; 2019 Jul; 99(9):769-773. PubMed ID: 31017250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating to Target(s) With Interleukin-17 Inhibitors.
    Lynde CW; Beecker J; Dutz J; Flanagan C; Guenther LC; Gulliver W; Papp K; Rahman P; Sholter D; Searles GE
    J Cutan Med Surg; 2019; 23(2_suppl):3S-34S. PubMed ID: 30742778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study.
    Gasslitter I; Kirsten N; Augustin M; Torz K; Mrowietz U; Eyerich K; Puig L; Hoetzenecker W; Schütz-Bergmayr M; Weger W; Wolf P; Reider N; Ratzinger G; Papageorgiou K; Meier TO; Maul JT; Anzengruber F; Navarini AA
    Arch Dermatol Res; 2019 Jul; 311(5):421-424. PubMed ID: 30879102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.